AWM Investment Company Inc. Reduces Stock Position in Repligen Corporation $RGEN

Key Points

• AWM Investment Company Inc. has reduced its stake in Repligen Corporation by 12.3%, selling 8,000 shares to hold 57,000 shares valued at approximately $7.25 million.
• Repligen's recent earnings report showed a miss on EPS estimates, with earnings of $0.37 compared to the expected $0.40, despite a revenue increase of 14.8% year-over-year.
• Several hedge funds have recently modified their holdings in Repligen, with notable increases including a 110.3% boost in position by Center for Financial Planning Inc.

AWM Investment Company Inc. trimmed its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 12.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 57,000 shares of the biotechnology company's stock after selling 8,000 shares during the period. AWM Investment Company Inc. owned 0.10% of Repligen worth $7,253,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Alliance Wealth Advisors LLC UT boosted its stake in Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after buying an additional 89 shares during the last quarter. State of Michigan Retirement System lifted its stake in shares of Repligen by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after purchasing an additional 100 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after purchasing an additional 100 shares in the last quarter. State of Wyoming lifted its stake in shares of Repligen by 5.2% in the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock valued at $297,000 after purchasing an additional 115 shares in the last quarter. Finally, Signaturefd LLC lifted its stake in shares of Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Up 3.3%

Shares of NASDAQ:RGEN traded up $3.98 during mid-day trading on Friday, hitting $124.56. 1,043,994 shares of the company traded hands, compared to its average volume of 653,843. The firm has a market cap of $7.01 billion, a P/E ratio of -498.22, a PEG ratio of 2.29 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The firm's 50 day simple moving average is $121.53 and its 200 day simple moving average is $129.29.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. Repligen's revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the company's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company's stock, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RGEN shares. Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a research note on Tuesday, July 22nd. Wells Fargo & Company reduced their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Evercore ISI reduced their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Barclays started coverage on Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price objective on the stock. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $169.55.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.